Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118278 | 1.00 | IDO1 (0.76) | IDO1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30056167 | 0.90 | IDO1 (0.74) | IDO1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL21496551 | 0.89 | IDO1 (0.73) | IDO1LMNAMEN1KMT2AMAPT | |
| SCHEMBL21496552 | 0.89 | IDO1 (0.73) | IDO1LMNAMEN1KMT2AMAPT | |
| SCHEMBL30056965 | 0.88 | IDO1 (0.74) | IDO1RAB9AMEN1KMT2A | |
| SCHEMBL21496273 | 0.86 | IDO1 (1.00) | IDO1SMN1; SMN2 | |
| SCHEMBL21496274 | 0.86 | IDO1 (1.00) | IDO1SMN1; SMN2 | |
| SCHEMBL30055286 | 0.86 | IDO1 (1.00) | IDO1SMN1; SMN2 | |
| SCHEMBL24118299 | 0.86 | IDO1 (1.00) | IDO1SMN1; SMN2 | |
| SCHEMBL24117951 | 0.81 | IDO1 (0.67) | IDO1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478461-B2 | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478461-B2 | [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | IDO1 1/4885NPC1 1312/4885RAB9A 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.